HEBEI CHANGSHAN
GenericsHEBEI CHANGSHAN is a generic drug manufacturer focused on Cardiovascular, Respiratory.
HEBEI CHANGSHAN's Key Drugs
HEBEI CHANGSHAN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
HEBEI CHANGSHAN's Recent FDA Approvals
New NDA/BLA approvals for HEBEI CHANGSHAN over the last two years — novel drugs only, excluding generics and label supplements.
HEBEI CHANGSHAN's Therapeutic Areas
HEBEI CHANGSHAN's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HEBEI CHANGSHAN's Top Competitors
HEBEI CHANGSHAN's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HEBEI CHANGSHAN Pipeline Snapshot
Active clinical trials for HEBEI CHANGSHAN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-01-07
- Latest
- 2026-01-07
- Applications
- 1